STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1401 by analyst upside · 2026-08-12
ANIP
ANI Pharmaceuticals, Inc.
Healthcare · Market Cap $2B · P/E 16.2x
ANALYST PRICE TARGET
+45.4%
implied upside to consensus target
Current Price $74.53
Consensus Target $108.38
Bull Target $121.0
Bear Target $90.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
4
Hold
1
Sell
0
52-Week Low $70.15
52-Week High $99.5
YTD Return -5.0%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) 16.2x
Forward P/E 7.1x
EPS (TTM) $4.59
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $978M
Profit Margin 11.1%
52-WEEK RANGE
52-Week Low $70.15
52-Week High $99.5
Current Price $74.53
Bear Target $90.0
Bull Target $121.0
● Now $74.53 ● Target $108.38
TRADING DATA
Avg Volume 335K
YTD Return -5.0%
Analyst Count 8
Consensus Buy
Upside to Target +45.4%
Last Updated 2026-08-12

ANALYST SUMMARY

ANI Pharmaceuticals, Inc. (ANIP) is currently trading at $74.53 with a Wall Street consensus price target of $108.38, implying potential upside of 45.4% over the next 12 months. 8 analysts currently cover ANIP, with a consensus rating of Buy - 88% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $121.0, while the most cautious has a target of $90.0.

ANIP operates in the Healthcare sector with a market capitalisation of $2B. The stock is down 5.0% year-to-date and is currently trading near the lower end of its 52-week range of $70.15 – $99.5.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ANIP, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Guggenheim - Reiterated
Buy → Buy 2026-01-16 62% win rate (8 calls)
Barclays ● Initiated
Overweight 2025-12-09 Building track record
Guggenheim - Reiterated
Buy → Buy 2025-11-10 62% win rate (8 calls)
Truist Securities - Reiterated
Hold → Hold 2025-10-09 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2025-09-24 43% win rate (7 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2025-09-17 31% win rate (48 calls)
Guggenheim - Reiterated
Buy → Buy 2025-09-08 62% win rate (8 calls)
Truist Securities - Reiterated
Hold → Hold 2025-08-11 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
61
out of 100
Coverage depth
17/30
Consensus clarity
22/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →